

Response letter

January 26, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 15793-Review.docx).

Title: Adjuvant therapy of gastric cancer: What did we learn since INT0116?

Authors: Alexandre A. Jácome, Ajith K. Sankarankutty, José Sebastião dos Santos.

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 15793

We are grateful with the comments and suggestions raised by the reviewers, which, certainly, improved the quality of our paper. Below, we explain all the suggestions and corrections that have been made:

1. Reviewer 1114: According to suggestions of the reviewer, we shortened the paragraphs "Individualized treatment" and "Perspectives". In the section "Surgical treatment", we presented the data about the extent of lymphadenectomy and discussed about the paramount importance of surgical resection. We corrected the reference style according to the instructions.
2. Reviewer 57560: No suggestions.
3. Reviewer 182909: No suggestions.

4. Reviewer 160226: We accepted the suggestions, excluding the comments related to the extent of lymphadenectomy, and grouped the informations about risk recurrence in the same paragraph.

We added the year's studies in table.

We also would like to stick the same unit in the columns, however it was not possible, because the studies cited do not offer these data in the same unit. For example, ARTIST study presents the data through Hazard Ratio, while Kim et al. presents survival data in percentage in each period of time.

In the section "Adjuvant chemotherapy", we describe the limitations of the previous studies, and we decided not to cite references, because they are in large numbers and have low relevance compared to current trials.

In the section "Adjuvant chemotherapy", in the second paragraph, we mentioned the meta-analysis, which does not include XELOX and S1 studies. So that, according to suggestions, we combined this second paragraph with the introductory one.

We decided to begin our paper with the section "Adjuvant chemoradiotherapy" because the pivotal study INT0116 was earlier than the MAGIC and ACCORD-07 studies. The results of perioperative chemotherapy studies could be generalized to gastric cancers, since 74% of patients in MAGIC trial were gastric cancer patients, and this study has a relevant sample size (>500 patients).

We added the year's studies in all tables.

5. Reviewer 70821: No suggestions.
6. Reviewer 2438232: No suggestions.

We also included the PMID and DOI in all the cited articles.

Thank you for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Alexandre A. A. Jácome, MD, PhD